Recall of Sandoz Apixaban 2.5mg and 5mg Tablets Due to Outdated Leaflet
Areazine synthesizes this MHRA medicine alert directly from MHRA's official public data feed. See our methodology for full source attribution and refresh cadence.
Sandoz Limited has notified the MHRA of a recall for certain batches of Apixaban 2.5mg and 5mg tablets because the patient information leaflet contains outdated information.
What this MHRA medicine alert tells you, and what most readers miss
This notice was issued by MHRA on April 7, 2026 and geographically references United Kingdom. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Alerts - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, MHRA, medicine.
Recall Article
What Happened
The Patient Information Leaflet included in specified batches of Apixaban tablets does not contain up-to-date information, as notified by Sandoz Limited to the MHRA.
Which Products Are Affected
The affected products are Apixaban 2.5mg and 5mg Tablets manufactured by Sandoz Limited. No specific model numbers, UPCs, quantities, or date ranges were provided in the notification.
What You Should Do
Consumers should refer to the official MHRA alert for information on the affected batches and any recommended actions.
Why This Matters
This recall addresses a defect in product information to ensure accurate usage, but it is classified as low severity with minimal safety impact.
Source
MHRA alert: Class 4 Medicines Defect Notification
Original source: MHRA Official Notice ↗
Related Medicine Alerts
All Medicine Alerts →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this MHRA medicine alert: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (931 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this MHRA medicine alert.